MUC1 and familial pancreatic carcinoma: Western blot confirmed stable MUC1 expression in multiple pancreatic cancer cell lines (PANC-1, BxPC-3, MIA PaCa-2), providing a molecular rationale for MUC1-targeted immunotherapy.